Jody A. Charnow, Editor

Jody A. Charnow, Editor

Jody Charnow is the editor of Renal and Urology News.

Most Recent Articles by Jody A. Charnow, Editor

Biologics Combo Shows Promise As First-Line mRCC Therapy

Biologics Combo Shows Promise As First-Line mRCC Therapy

By

In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.

Sunitinib Dose Escalation May Benefit mRCC Patients

Sunitinib Dose Escalation May Benefit mRCC Patients

By

Added progression-free survival and prolonged overall survival possible, according to investigators.

Kidney Cancer Brain Metastases Not On the Rise

Kidney Cancer Brain Metastases Not On the Rise

By

Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.

Single RCC Bone Metastasis Predicts Better Survival

Single RCC Bone Metastasis Predicts Better Survival

By

Bone surgery should be considered in patients with solitary bone metastasis and no concomitant visceral metastases, according to investigators.

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

By

Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.

More Articles by Jody A. Charnow, Editor

Sign Up for Free e-newsletters